Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
Three-Drug Combination Extends Survival for Patients with Multiple MyelomaA phase III clinical trial demonstrates that adding the drug bortezomib to a commonly used two-drug regimen extends survival in patients with newly diagnosed multiple myeloma.
-
NCTN/NCORP Data Archive: Expanding Access to Clinical Trial DataNCI is launching the NCTN/NCORP Data Archive, a centralized repository of patient-level data from phase III clinical trials conducted by NCI’s NCTN and NCORP trials programs and the National Cancer Institute of Canada-Clinical Trials Group.
-
New Therapy Benefits Patients with Neuroendocrine TumorsResults from a clinical trial suggest that 177 Lu-Dotatate may soon be a new treatment option for some patients with advanced neuroendocrine tumors.
-
Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis ComplicationsIn a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.
-
Genome Study Points to New Subtypes of Esophageal CancerA new study by The Cancer Genome Atlas Research Network could help classify esophageal cancers according to their genetic and molecular alterations and identify potential new treatment options.
-
Shifts Seen in Tobacco Product Types Purchased in USThe consumption of cigarettes, small cigars, and chewing tobacco has declined over the past 15 years, according to a new study. These declines were partially offset by a rise in consumption of large cigars, pipe tobacco, and snuff.
-
The Global Economic Burden of Tobacco: An Interview with Dr. Mark ParascandolaNCI’s Dr. Mark Parascandola answers questions about The Economics of Tobacco and Tobacco Control, the latest in a series of monographs on tobacco use and tobacco control, which was co-written with the World Health Organization.
-
Ibrutinib Relieves Chronic Graft-Versus-Host Disease SymptomsThe targeted cancer therapy ibrutinib can effectively treat the symptoms of chronic graft-versus-host disease, a common and serious complication of allogeneic stem cell transplants, findings from a small clinical trial show.
-
FDA Approves Rucaparib for BRCA-Positive Ovarian CancerThe FDA has approved rucaparib for women with BRCA-positive advanced ovarian cancer based on findings from two small clinical trials showing that it shrank tumors.
-
For Some Breast Cancer Survivors, Drug May Reduce Treatment-Related Joint PainResearchers have found that duloxetine (Cymbalta®), a drug most commonly used to treat depression, may also reduce joint pain caused by aromatase inhibitors in some women being treated for early-stage breast cancer.
-
New Mouse Model Closely Mimics Most Common Leukemia in InfantsResearchers have created a long-sought-after mouse model for an aggressive form of acute lymphoblastic leukemia that occurs commonly in infants and that the researchers believe can accelerate the development of new therapies for the disease.
-
New on NCI’s Websites for December 2016An NCI Cancer Currents blog post that provides an update on new content of interest to the cancer community recently added to NCI’s websites.
-
New Targeted Therapies Show Promise for Treating Advanced GISTTwo new targeted therapies have shown promise in patients with gastrointestinal stromal tumors (GIST) that have developed resistance to standard therapies.
-
Brain Cancer’s Cholesterol Addiction May Offer New Treatment StrategyBrain cancer cells are heavily dependent on a constant supply of cholesterol to survive, a new study suggests. And in mice with brain tumors, treatment with a cholesterol-depleting drug slowed tumor growth and improved survival.
-
Single Tumor Cells Reveal Clues to Biology of Multiple MyelomaA study suggests that individual tumor cells circulating in the blood of patients with multiple myeloma may be a new source of information about the genetic changes driving the disease.
-
FDA Approves New Use for Daratumumab in Multiple MyelomaThe FDA has approved daratumumab, in combination with either of two other standard therapies, in patients with multiple myeloma whose disease has progressed after only a single prior treatment course.
-
Immune-Cell Traps May Aid Cancer MetastasisCancer cells may exploit a normal function of neutrophils, the most common form of white blood cell, to help form metastatic tumors, a new study suggests.
-
FDA Approves Nivolumab for Head and Neck CancerThe FDA has approved nivolumab for squamous cell carcinoma of the head and neck that has progressed during chemotherapy with a platinum-based drug or that has recurred or metastasized after platinum-based chemotherapy.
-
Prescription Subsidies Reduce Breast Cancer Treatment DisparitiesA new study has found that subsidies for prescription drugs can improve the use of adjuvant therapy in women with early-stage breast cancer and help reduce disparities in the use of these proven treatments among black and Hispanic women.
-
Device Uses Cancer Cells' Mass to Predict Response to TreatmentScientists have designed a device that measures the mass of single cancer cells to predict how cells respond to drug treatment. The technology could potentially help clinicians determine whether a drug effectively kills cancer cells.